Skandinaviska Enskilda Banken (SEB)’s Denali Therapeutics DNLI Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-43,245	Closed	-$605K	–	815
2025 Q2	$605K	Hold	43,245	–	–	﹤0.01%	690
2025 Q1	$588K	Hold	43,245	–	–	﹤0.01%	677
2024 Q4	$875K	Hold	43,245	–	–	﹤0.01%	668
2024 Q3	$1.26M	Hold	43,245	–	–	0.01%	651
2024 Q2	$1M	Hold	43,245	–	–	﹤0.01%	642
2024 Q1	$887K	Sell	43,245 -304,958	-88%	-$5.73M	﹤0.01%	669
2023 Q4	$7.47M	Hold	348,203	–	–	0.04%	314
2023 Q3	$7.18M	Hold	348,203	–	–	0.05%	308
2023 Q2	$10.3M	Buy	348,203 +41,233	+13%	+$1.16M	0.07%	258
2023 Q1	$7.07M	Sell	306,970 -2,122	-0.7%	-$58.4K	0.05%	320
2022 Q4	$8.6M	Buy	309,092 +17,784	+6%	+$529K	0.06%	273
2022 Q3	$8.94M	Buy	291,308 +78,485	+37%	+$2.55M	0.07%	257
2022 Q2	$6.26M	Buy	212,823 +74,324	+54%	+$1.95M	0.05%	320
2022 Q1	$4.46M	Sell	138,499 -64	-0%	-$2.2K	0.03%	431
2021 Q4	$6.24M	Buy	138,563 +6,509	+5%	+$308K	0.03%	375
2021 Q3	$6.66M	Buy	132,054 +102,269	+343%	+$5.76M	0.04%	358
2021 Q2	$2.34M	Buy	29,785 +3,685	+14%	+$228K	0.01%	621
2021 Q1	$1.49M	Hold	26,100	–	–	0.01%	739
2020 Q4	$2.19M	Buy	+26,100	New	+$1.58M	0.02%	618

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s DNLI Position: Q3 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 43,245 shares — an estimated $605K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in DNLI in Q4 2020 and held it in 19 quarters. The position peaked at $10.3M in Q2 2023. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

Skandinaviska Enskilda Banken (SEB) reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 43,245 Denali Therapeutics shares in Q3 2025, an estimated $605K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Denali Therapeutics in Q4 2020 and held it in 19 quarters.
Skandinaviska Enskilda Banken (SEB)'s Denali Therapeutics position peaked at $10.3M in Q2 2023.
240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2025, filed 7 Nov 2025.